IgA Nephropathy Access: Trutakna, Filspari, Tarpeyo, Fabhalta, and Voyxact

The therapeutic landscape for immunoglobulin A (IgA) nephropathy (IgAN)—a progressive autoimmune kidney disease that stands as a leading cause of end-stage renal disease (ESRD) in young adults—has undergone a rapid expansion. Historically, clinical management was limited to non-specific supportive care, including maximum-tolerated doses of renin-angiotensin system (RAS) inhibitors (ACE inhibitors or ARBs) and systemic corticosteroids, which carried severe long-term toxicity. However, between 2021 and mid-2026, the FDA approved six targeted therapies across five distinct mechanisms of action.

This rapid expansion culminated on July 7, 2026, with the accelerated approval of Trutakna (atacicept, Vera Therapeutics), a first-in-class dual B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) inhibitor. For nephrology clinical teams, specialty pharmacies, and payer medical directors, this multi-agent market creates significant complexity in drug sequencing, prior authorization (PA) design, and financial risk management.

---

Quick answer

What is the scenario question? If I am a nephrology access or payer team standing up IgA nephropathy coverage in mid-2026, how do the six approved agents differ by mechanism, evidence, price, and access friction - and where does the just-approved Trutakna fit?

Direct Answer: IgA nephropathy now has six FDA-approved targeted therapies across five mechanisms. Trutakna (atacicept, Vera)—approved under the accelerated pathway on July 7, 2026—is the first dual BAFF/APRIL inhibitor, demonstrating a 46% reduction in proteinuria at week 36 in the ORIGIN 3 trial, launching at a wholesale acquisition cost (WAC) of $32,700 per 28-day carton (~$425,000 per year) as a once-weekly subcutaneous injection. It enters a market populated by:

1. Filspari (sparsentan, Travere): Dual ETA/ARB; full approval Sep 2024; WAC ~$118,800/yr ($9,900/30-day); REMS safety monitoring simplified in Aug 2025.
2. Tarpeyo (targeted-release budesonide, Calliditas): Oral corticosteroid; full approval Dec 2023; WAC ~$170,000/yr.
3. Fabhalta (iptacopan, Novartis): Complement Factor B inhibitor; approved Aug 8, 2024.
4. Vanrafia (atrasentan, Novartis): Selective endothelin A (ETA) receptor antagonist; approved Apr 2, 2025; ALIGN trial showed a 38% reduction in UPCR at week 36.
5. Voyxact (sibeprenlimab, Otsuka): Selective anti-APRIL monoclonal antibody; approved Nov 25, 2025; WAC ~$390,000/yr.

All agents except Tarpeyo and Filspari (which converted to full status) are currently approved under the FDA's accelerated pathway based on the surrogate endpoint of proteinuria reduction, with confirmatory long-term eGFR data pending. Payer prior authorization is universal, with ICER’s December 2025 draft evidence report setting value-based price benchmarks (e.g., $60,000–$80,000/yr for Filspari) well below current WAC levels.

---

Who this is for

• Nephrology Market Access and Payer Relations Teams: Navigating step-therapy designs, rebate negotiation across therapeutic classes, and prior-authorization documentation.
• Specialty Pharmacy Directors: Managing limited distribution networks, coordinating manufacturer-sponsored hub programs, and overseeing REMS compliance.
• Clinical Nephrologists and Nurse Practitioners: Selecting patients based on trial-entry criteria, documenting baseline eGFR and proteinuria, and managing prior-authorization appeals.
• Payer Medical Directors and Actuaries: Evaluating the budget impact of B-cell directed therapies, setting medical policy criteria, and translating HTA (ICER) value benchmarks.

---

Methodology, in one paragraph

The access landscape presented in this comparison is synthesized from primary regulatory, clinical, and health technology assessment (HTA) documents. FDA approval dates, pathways, and product labels are extracted from the Drugs@FDA database. Pivotal clinical efficacy and safety endpoints are drawn from the published records of the registrational trials: ORIGIN 3 (atacicept), APPLAUSE-IgAN (iptacopan), ALIGN (atrasentan), PROTECT (sparsentan), and NefIgArd (targeted-release budesonide). Pricing benchmarks reflect the manufacturer-disclosed Wholesale Acquisition Cost (WAC) at the time of launch, updated through July 2026. Value benchmarks and class-wide budget impacts are analyzed using the Institute for Clinical and Economic Review (ICER) B-Cell Directed Therapies for IgA Nephropathy Draft Evidence Report (December 2025). REMS safety requirements are verified against the active FDA REMS database. For prior-authorization templates, see payer coverage matrix specialty drugs; for general specialty hub workflows, see patient assistance prior auth workflow; and for background on the atacicept development path, see the atacicept IgA nephropathy PDUFA preview.

---

Pathophysiology and the 2025 KDIGO Clinical Guidelines

To evaluate payer coverage policies, we must ground them in clinical guidelines. The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Management of Glomerular Diseases provides the framework:

• The Pathogenesis Cascade: Primary IgA nephropathy is an autoimmune glomerulonephritis driven by a "four-hit" hypothesis: (1) elevated circulating levels of Gd-IgA1; (2) synthesis of IgG or IgA autoantibodies directed against Gd-IgA1; (3) formation of Gd-IgA1–antibody immune complexes; and (4) mesangial deposition of these complexes, which activates mesangial cell proliferation, complement cascade, and cytokine release, leading to tubulointerstitial fibrosis and glomerulosclerosis.
• The KDIGO Optimization Period: KDIGO guidelines mandate that the foundation of IgAN management is optimized supportive care. Clinicians must initiate maximally tolerated, stable doses of RAS inhibitors (ACE inhibitors or ARBs) for at least 3 to 6 months. Blood pressure must be controlled to target levels (<120 mmHg systolic), and cardiovascular risk must be managed.
• Risk Stratification and Targeted Intervention: After the optimization period, if the patient's proteinuria remains $\ge$ 0.75 to 1.0 g per day (or urine protein-to-creatinine ratio [UPCR] $\ge$ 0.75 to 1.0 g/g), the patient is considered at high risk for progressive kidney function decline. KDIGO recommends that these high-risk patients be considered for targeted therapies. The guidelines advise incorporating targeted options based on patient characteristics, hemodynamic risk, and contraindications.

This KDIGO optimization requirement forms the basis of payer prior-authorization policies. Payer policies universally require documentation that the patient has failed to achieve therapeutic targets despite optimized RAS blockade.

---

Detailed Profiles of the Six Targeted Therapies and Key Trials

1. Tarpeyo (targeted-release budesonide)

Tarpeyo is an oral, delayed-release formulation of the corticosteroid budesonide. It is designed with a gastro-resistant coating that delays release until it reaches the ileum, targeting the Peyer's patches where Gd-IgA1 is produced. Because budesonide undergoes 90% first-pass hepatic metabolism, systemic corticosteroid exposure is reduced.

• The NefIgArd Trial: The Phase 3 trial randomized 364 patients with biopsy-confirmed IgAN, eGFR $\ge$ 30 mL/min/1.73m², and proteinuria $\ge$ 1.0 g/day to Tarpeyo 16 mg once daily or placebo for 9 months.
• Efficacy: At 9 months, Tarpeyo-treated patients achieved a 30% reduction in UPCR compared to placebo. At 2 years (after a 15-month treatment-free follow-up), Tarpeyo demonstrated a statistically significant 6.0 mL/min/1.73m² eGFR benefit over placebo, leading to full FDA approval in December 2023.

2. Filspari (sparsentan)

Sparsentan is a single molecule that acts as a dual endothelin type A (ETA) and angiotensin II type 1 (AT1) receptor antagonist, targeting both hemodynamic and inflammatory pathways.

• The PROTECT Trial: The Phase 3 trial randomized 404 patients with biopsy-confirmed IgAN and proteinuria $\ge$ 1.0 g/day to sparsentan or the active comparator irbesartan.
• Efficacy: At week 36, sparsentan-treated patients achieved a 49.8% reduction in proteinuria compared to irbesartan. The confirmatory 2-year eGFR analysis showed a statistically significant preservation of kidney function, resulting in full approval in September 2024.

3. Fabhalta (iptacopan)

Iptacopan is an oral, selective inhibitor of Factor B, a rate-limiting protease of the alternative complement pathway, preventing local complement-mediated tissue damage.

• The APPLAUSE-IgAN Trial: The Phase 3 trial randomized patients with IgAN and proteinuria $\ge$ 1.0 g/day to iptacopan 200 mg twice daily or placebo.
• Efficacy: The primary endpoint showed a 38.3% reduction in UPCR at week 36 compared to placebo, leading to accelerated approval on August 8, 2024. Confirmatory eGFR slope data is pending.

4. Vanrafia (atrasentan)

Atrasentan is an oral, selective endothelin type A (ETA) receptor antagonist, reducing mesangial cell activation and proteinuria.

• The ALIGN Trial: The Phase 3 trial randomized patients with IgAN and proteinuria $\ge$ 1.0 g/day to atrasentan 0.75 mg once daily or placebo.
• Efficacy: Demonstration of a 38% reduction in UPCR at week 36 compared to placebo (placebo-adjusted; −38.1% from baseline versus −3.1% for placebo). The final 2.5-year ALIGN analysis also showed a slowing of kidney function decline (eGFR slope) versus placebo, supporting its clinical profile, with continued approval contingent on confirmatory evidence.

5. Voyxact (sibeprenlimab)

Sibeprenlimab is a humanized monoclonal antibody self-administered as a once-monthly (every four weeks) subcutaneous injection that binds to and neutralizes APRIL, a cytokine driving Gd-IgA1 production.

• The VISIONARY Trial: The Phase 3 trial's prespecified interim analysis (n=320) showed a 51% placebo-adjusted reduction in proteinuria at nine months (−50% with Voyxact versus +2% with placebo; P<0.0001), leading to accelerated approval on November 25, 2025.

6. Trutakna (atacicept)

Atacicept is a recombinant fusion protein administered as a weekly subcutaneous self-injection that binds to and neutralizes both BAFF and APRIL.

• The ORIGIN 3 Trial: The Phase 3 trial randomized patients with IgAN and proteinuria $\ge$ 1.0 g/day to atacicept 150 mg once weekly or placebo.
• Efficacy: At week 36, atacicept-treated patients achieved a 46% reduction in proteinuria compared to placebo. Confirmatory 2-year eGFR slope data is expected in Q3 2026, with an sBLA planned for Q4 2026.

---

How are the agents priced and what is the access friction (REMS, specialty pharmacy)?

The annual WAC prices for these therapies show a significant split between oral non-biologics and B-cell directed biologics:

Annual IgA Nephropathy WAC Benchmarks (2026):
- Filspari (sparsentan): ~$118,800 per year ($9,900/30-day)
- Tarpeyo (budesonide): ~$170,000 per 9-month course
- Fabhalta (iptacopan): ~$312,000 per year
- Voyxact (sibeprenlimab): ~$390,000 per year
- Trutakna (atacicept): ~$425,000 per year ($32,700/28-day carton)

This pricing structure creates intense payer scrutiny. Prior authorization is required by all commercial, Medicare Part D, and Medicaid plans.

REMS and Safety Monitoring Friction

Beyond financial barriers, clinical access teams must navigate safety programs:

• Filspari REMS: Sparsentan carries a boxed warning for hepatotoxicity and embryo-fetal toxicity. To mitigate these risks, the FDA mandated the Filspari REMS program, requiring prescriber and pharmacy certification, monthly liver transaminase and bilirubin monitoring, and monthly pregnancy tests for females of reproductive potential. On August 27, 2025, the FDA simplified the REMS, easing the reporting burden for certified clinics, but the laboratory monitoring requirements remain a logistical gate.
• Vanrafia REMS: Atrasentan, as an endothelin receptor antagonist, carries a similar risk of embryo-fetal toxicity, requiring enrollment in a dedicated REMS program. It also requires baseline and periodic monitoring of liver function and fluid retention.
• Fabhalta REMS: Iptacopan carries a boxed warning for serious meningococcal infections due to its complement-inhibiting mechanism. The Fabhalta REMS requires patients to receive meningococcal vaccines at least two weeks before initiating therapy and to carry a patient safety card.
• Trutakna and Voyxact (B-Cell Biologics): Do not require a formal FDA REMS program. However, as B-cell–directed immunosuppressants, they require baseline screening for tuberculosis and hepatitis B, and monitoring for serious infections during therapy.

---

Where does the just-approved Trutakna (atacicept) fit among B-cell therapies?

The approval of Trutakna (atacicept) on July 7, 2026, establishes a competitive dynamic with Voyxact (sibeprenlimab) in the B-cell directed class.

Dual BAFF/APRIL vs. Selective anti-APRIL

• The Biological Rationale: BAFF and APRIL are structurally related cytokines that control B-cell survival and plasma cell differentiation. By blocking both cytokines, atacicept is designed to provide broader suppression of Gd-IgA1 production than sibeprenlimab, which targets APRIL alone.
• Administration Setting: Both agents are self-administered subcutaneous biologics dispensed through the specialty-pharmacy channel, but they differ in dosing frequency. Atacicept (Trutakna) is a once-weekly subcutaneous autoinjector (150 mg), whereas sibeprenlimab (Voyxact) is dosed once every four weeks subcutaneously. Because both are self-injected biologics rather than office-infused drugs, both are typically routed through the Pharmacy Benefit and require prior authorization under commercial specialty-drug formularies — the access mechanics of benefit verification medical versus pharmacy benefit specialty drugs still apply to PA documentation and limited-distribution setup, but neither drug is a buy-and-bill medical-benefit infusion. The weekly-versus-monthly cadence is the practical differentiator for adherence, refill workflows, and PA reauthorization timing.

The Regulatory Timeline

Vera Therapeutics plans to submit a supplemental Biologics License Application (sBLA) for full approval in Q4 2026, utilizing confirmatory 2-year eGFR data from the ORIGIN 3 trial expected in Q3 2026. This fast transition is designed to convert its accelerated approval to full approval before competitors, easing payer skepticism regarding surrogate-endpoint durability.

---

Payer Prior-Authorization Policy Synthesis

To assist clinical access teams, we synthesize the prior-authorization criteria implemented by major national payers (such as UnitedHealthcare and Cigna) for targeted IgAN therapies:

UnitedHealthcare (UHC Commercial Policy)

• Trial Period Requirement: The patient must have been on a stable, optimized dose of an ACE inhibitor or ARB for at least 3 months (or have a documented contraindication).
• Proteinuria Threshold: Documented urine protein-to-creatinine ratio (UPCR) $\ge$ 0.75 g/g or 24-hour urine protein $\ge$ 1.0 g within the past 30 days.
• eGFR Restriction: eGFR must be $\ge$ 30 mL/min/1.73m² (or $\ge$ 15 mL/min/1.73m² for sparsentan, depending on the specific policy update).
• Step-Therapy: UHC commercial plans require a trial and failure of, or contraindication to, first-line supportive therapies and low-cost options (such as Tarpeyo or Filspari) before B-cell directed therapies are approved.
• Initial Approval: 6 months (Tarpeyo) or 12 months (Filspari/biologics).
• Reauthorization: Requires documentation of therapeutic response, defined as a reduction in proteinuria or stabilization of the eGFR slope, and no progression to ESRD.

Cigna (National Formulary Policy)

• Optimization: Maximally tolerated RAS inhibitor therapy for $\ge$ 3 months.
• Proteinuria: Baseline UPCR $\ge$ 0.75 g/g or 24-hour protein $\ge$ 1.0 g.
• Specialist Prescriber: Must be prescribed by, or in consultation with, a nephrologist.
• Tapering Rules (Corticosteroids): If the patient is on systemic corticosteroids, the policy requires a plan to taper and discontinue systemic steroids within 2 weeks of initiating targeted therapy (such as sparsentan).
• Initial Approval: 12 months.

---

What are payers and ICER likely to do with this class?

With multiple high-cost agents competing for a relatively small patient population (~130,000 diagnosed patients in the U.S.), payers are implementing strict utilization management criteria.

The ICER Value Benchmarks

The December 2025 ICER Draft Evidence Report evaluated B-cell directed therapies for IgA nephropathy. The report highlighted that while targeted therapies offer clinical benefit, their launch prices exceed traditional cost-effectiveness thresholds:

• The Value Gap: ICER’s health-benefit price benchmark for these agents sits significantly below their WAC list prices. For example, ICER set a value benchmark of $60,000 to $80,000 per year for sparsentan, compared to its actual WAC list price of ~$118,800.
• The B-Cell Discount Target: The report indicated that for B-cell directed therapies (sibeprenlimab and atacicept) to meet the $100,000–$150,000 per QALY threshold, they would require discounts of 65% to 75% off their planned list prices (~$390K–$425K), establishing a target value of $90,000 to $110,000 per year.

Payer Utilization Management Strategies

Based on the ICER report and clinical guidelines, payers are structuring prior-authorization criteria using three gates:

1. RAS Blockade Optimization: Payer policies universally require that the patient must have been on a stable, maximally tolerated dose of an ACE inhibitor or ARB for at least 3 to 6 months before initiating targeted therapy.
2. Proteinuria Thresholds: To match clinical trial entry criteria, payers require documentation of significant proteinuria (typically defined as a UPCR $\ge$ 0.75 g/g or $\ge$ 1.0 g/g, or 24-hour urine protein excretion $\ge$ 1.0 g).
3. Step-Therapy and Sequencing: Commercial plans are beginning to implement step-therapy protocols, requiring patients to "fail" lower-cost options (such as Tarpeyo or Filspari) before approving B-cell biologics (Trutakna or Voyxact). The $118,800 WAC for Filspari represents a significant cost advantage over the $425,000 WAC for Trutakna, prompting payers to mandate sparsentan as a first-line step.

---

FAQ

When was Trutakna (atacicept) approved and what does it cost?

Trutakna (atacicept-vymj) received FDA accelerated approval on July 7, 2026, for the reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. It is priced at a WAC list price of $32,700 per 28-day carton (~$425,000 per year), administered as a once-weekly subcutaneous injection.

How is atacicept different from sibeprenlimab?

Atacicept (Trutakna) is a dual BAFF and APRIL inhibitor administered as a weekly subcutaneous self-injection. Sibeprenlimab (Voyxact, approved Nov 25, 2025) is a selective anti-APRIL monoclonal antibody administered as a once-monthly (every four weeks) subcutaneous injection.

Which IgA nephropathy drug has full (not accelerated) approval?

Filspari (sparsentan) achieved full approval in September 2024 following 2-year eGFR data from the PROTECT trial. Tarpeyo (targeted budesonide) achieved full approval in December 2023 based on 2-year eGFR data from the NefIgArd trial. The other four approved agents remain on accelerated approval.

What did ICER conclude about the B-cell therapies?

ICER's December 2025 draft report concluded that current list prices (~$390K–$425K) exceed cost-effectiveness thresholds. ICER estimated that a value-based price for B-cell therapies would sit between $90,000 and $110,000 per year, requiring discounts of up to 75% off list price.

---

Sources

1. Vera Therapeutics Trutakna FDA Approval: Vera Therapeutics Receives FDA Accelerated Approval for Trutakna (atacicept-vymj) for the Reduction of Proteinuria in Primary IgA Nephropathy, Vera Press Release, July 7, 2026. Vera Investor Relations.
2. ICER HTA Draft Evidence Report: B-Cell Directed Therapies for IgA Nephropathy: Draft Evidence Report, Institute for Clinical and Economic Review, December 10, 2025. ICER.org.
3. Otsuka Voyxact FDA Approval: Otsuka Receives FDA Accelerated Approval for VOYXACT (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary IgA Nephropathy, Otsuka Press Release, November 25, 2025. Otsuka-US.com.
4. Filspari WAC and FDA Label Conversion: FDA Grants Full Approval to FILSPARI (sparsentan) for Primary IgA Nephropathy, Travere Therapeutics Press Release, September 5, 2024. Travere.com.
5. FDA Drug Approval Packages: Drugs@FDA Database. FDA.gov.
6. ALIGN Trial Results for Atrasentan: Phase 3 ALIGN Study of Atrasentan in Patients with IgA Nephropathy, The Lancet, 2024.
7. KDIGO Clinical Guidelines: 2025 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases (Draft Update), Kidney Disease: Improving Global Outcomes, 2025. KDIGO.org.